The R&D Challenges in tackling Ebola

PhRMA October 1, 2014

This IFPMA video interview with Ripley Ballou, who's in charge of GlaxoSmithKline's (GSK’s) Ebola vaccine program in Rixensart, Belgium, was recorded soon after Ebola scientists and representatives from companies and regulatory bodies met at the World Health Organization’s (WHO’s) headquarters in Geneva, Switzerland, 4-5 September, to discuss how to speed up clinical development of vaccines, a process that normally takes years. Dr. Ripley Ballou, like many public health specialists, believes that vaccines will have an important role to play in stopping the catastrophic outbreak in West Africa, which has so far caused at least 6553 cases and more than 3000 deaths in Guinea, Sierra Leone, and Liberia. (Reported numbers; the real toll is known to be much higher.) (Geneva, 30 September 2014)